Methods for treating cancer and methods to improve the efficacy of T-cell re-induction therapies

What is AI technical title?
AI technical title is built by Patsnap AI team. It summarizes the technical point description of the patent document.
Combining anti-CD38 antibodies with T-cell re-induction agents like BCMAxCD3 bispecific antibodies addresses T cell exhaustion in tumor microenvironments, enhancing the efficacy of T-cell re-induction therapies by restoring T cell functionality and improving tumor cell killing.

KR102998587B1Active Publication Date: 2026-08-03JANSSEN BIOTECH INC +1

2 Cites 0 Cited by

Patent Information

Application Number: KR1020207035911
Authority / Receiving Office: KR · KR
Patent Type: Patents
Current Assignee / Owner
Priority Date: 2019-05-02
Filing Date: 2019-05-15
Publication Date: 2026-08-03
Estimated Expiration: 2039-05-15

Application Information

Patent Timeline

02 May 2019

Priority

15 May 2019

Application

KR1020207035911

03 Aug 2026

Publication

KR102998587B1

IPC: C07K16/28; A61K39/00; A61K39/395; A61K47/12; A61K47/20; A61K47/26; A61P35/00; C07K16/18

CPC: C07K16/2896; A61K39/39591; A61K47/12; A61K47/20; A61K47/26; A61P35/00; C07K16/18; C07K16/2809

Get more patent work done with AI

Run novelty searches—or use them for FTO, design risk, drafting and technical problem-solving.

AI Tagging

Application Domain

Boron compound active ingredients Antibody ingredients

Technology Topics

Antiendomysial antibodies Efficacy

Explore More Agents

Novelty Search
Search existing technologies and assess novelty
↗
FTO
Analyze whether a product may infringe others' patents
↗
Design FTO
Check prior-design risk for exterior design
↗
Drafting
Draft patent application text based on a technical solution
↗
Find Solutions with TRIZ
Generate feasible solution to solve your technical challenge
↗
IP MCP Servers
Connect trusted patent search and cited evidence to Claude, Cursor or your own AI workflow
↗

AI Technical Summary

Technical Problem

Tumors evade immune recognition by creating an immunosuppressive tumor microenvironment, leading to T cell exhaustion and impaired functionality, which impairs the efficacy of T-cell re-induced apoptosis therapies.

Method used

Administering a combination of anti-CD38 antibodies and T-cell re-induction therapeutic agents, such as BCMAxCD3 bispecific antibodies, to enhance T cell functionality and improve the efficacy of T-cell re-induction therapies.

Benefits of technology

Enhances the efficacy of T-cell re-induction therapies by restoring T cell functionality and improving tumor cell killing capacity, particularly in relapsed or refractory multiple myeloma cases.

✦ Generated by Eureka AI based on patent content.

Patent Text Reader

Abstract

The present invention provides a method for treating cancer in a subject and / or killing tumor cells, said method comprising the step of treating said cancer by administering a therapeutically effective amount of an anti-CD38 antibody and a T-cell redirecting therapeutic to said subject. The present invention provides a method for enhancing the efficacy of a T-cell redirecting therapeutic in a subject having cancer, said method comprising the step of administering an anti-CD38 antibody to said subject. The present invention also provides a method for treating multiple myeloma in a subject, said method comprising the step of treating said multiple myeloma by administering a therapeutically effective amount of a BCMAxCD3 bispecific antibody and an anti-CD38 antibody to said subject. The present invention also provides a pharmaceutical combination comprising a GPRC5DxCD3 bispecific antibody. The present invention also provides a kit comprising a pharmaceutical composition comprising a BCMAxCD3 bispecific antibody and an anti-CD38 antibody.

Need to check novelty before this filing date? Find Prior Art